Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 13

PMID 38473804

Authors

Paola Pastena

Hiran Perera

Alessandro Martinino

William Kartsonis

Francesco Giovinazzo

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, marked by poor outcomes and dismal prognosis. Due to the absence of targetable receptors, chemotherapy still represents the main therapeutic option. Therefore, current research is now focusing on understanding the specific molecular pathways implicated in TNBC, in order to identify novel biomarker signatures and develop targeted therapies able to improve its clinical management. With the aim of identifying novel molecular features characterizing TNBC, elucidating the mechanisms by which these molecular biomarkers are implicated in the tumor development and progression, and assessing the impact on cancerous cells following their inhibition or modulation, we conducted a literature search from the earliest works to December 2023 on PubMed, Scopus, and Web Of Science. A total of 146 studies were selected. The results obtained demonstrated that TNBC is characterized by a heterogeneous molecular profile. Several biomarkers have proven not only to be characteristic of TNBC but also to serve as potential effective therapeutic targets, holding the promise of a new era of personalized treatments able to improve its prognosis. The pre-clinical findings that have emerged from our systematic review set the stage for further investigation in forthcoming clinical trials.

Citing Articles

PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.

Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M Front Pharmacol. 2024; 15:1475998.

PMID: 39564119 PMC: 11573589. DOI: 10.3389/fphar.2024.1475998.

Fatty Acid Synthase as Interacting Anticancer Target of the Terpenoid Myrianthic Acid Disclosed by MS-Based Proteomics Approaches.

Capuano A, DUrso G, Gazzillo E, Lauro G, Chini M, Dauria M Int J Mol Sci. 2024; 25(11).

PMID: 38892106 PMC: 11172900. DOI: 10.3390/ijms25115918.

References

McNamara K, Oguro S, Omata F, Kikuchi K, Guestini F, Suzuki K . The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer. Breast Cancer Res Treat. 2016; 161(2):213-227. DOI: 10.1007/s10549-016-4050-2. View

Wang J, Zhu X, Xu X, Guo L, Shen G, Liu X . PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer. Int J Clin Exp Pathol. 2020; 10(7):7682-7691. PMC: 6965305. View

Chung Y, Kim H, Park S, Park I, Jang J, Choe J . Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Hum Pathol. 2015; 46(7):1027-35. DOI: 10.1016/j.humpath.2015.03.015. View

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R . A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008; 10(5):R74. PMC: 2614505. DOI: 10.1186/bcr2139. View

Giricz O, Calvo V, Pero S, Krag D, Sparano J, Kenny P . GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat. 2011; 133(2):607-15. DOI: 10.1007/s10549-011-1822-6. View

Wang C, Li Y, Huang B, Zhao Y, Yuan H, Guo D . EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Sci Rep. 2017; 7(1):15654. PMC: 5688137. DOI: 10.1038/s41598-017-15939-9. View

Maia Lobba A, Carreira A, Cerqueira O, Fujita A, DeOcesano-Pereira C, Osorio C . High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. PLoS One. 2018; 13(6):e0199254. PMC: 6021101. DOI: 10.1371/journal.pone.0199254. View

Gao Y, Kabotyanski E, Shepherd J, Villegas E, Acosta D, Hamor C . Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2022; 1(3):178-193. PMC: 8827906. DOI: 10.1158/2767-9764.crc-21-0106. View

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio M . The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. BMC Cancer. 2018; 18(1):586. PMC: 5967041. DOI: 10.1186/s12885-018-4500-9. View

10.

Limsakul P, Choochuen P, Charupanit G, Charupanit K . Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. Cancers (Basel). 2023; 15(2). PMC: 9856281. DOI: 10.3390/cancers15020403. View

11.

Cabezon T, Gromova I, Gromov P, Serizawa R, Wielenga V, Kroman N . Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics. 2012; 12(2):381-94. PMC: 3567861. DOI: 10.1074/mcp.M112.019786. View

12.

Sayed-Ahmed M, Hafez M, Al-Shabanah O, Al-Rejaie S, Aleisa A, Al-Yahya A . Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. Tumori. 2013; 99(4):545-54. DOI: 10.1177/030089161309900418. View

13.

Le U, Chen N, Balasenthil S, Lurie E, Yang F, Liu S . Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep. 2022; 12(1):19504. PMC: 9663828. DOI: 10.1038/s41598-022-22417-4. View

14.

Kothari C, Osseni M, Agbo L, Ouellette G, Deraspe M, Laviolette F . Machine learning analysis identifies genes differentiating triple negative breast cancers. Sci Rep. 2020; 10(1):10464. PMC: 7320018. DOI: 10.1038/s41598-020-67525-1. View

15.

Zhang Y, Liu F, Zhang C, Ren M, Kuang M, Xiao T . Non-SMC Condensin I Complex Subunit D2 Is a Prognostic Factor in Triple-Negative Breast Cancer for the Ability to Promote Cell Cycle and Enhance Invasion. Am J Pathol. 2019; 190(1):37-47. DOI: 10.1016/j.ajpath.2019.09.014. View

16.

Chen L, Zhang Z, Yi Z, Li J . MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Br J Cancer. 2017; 117(1):78-88. PMC: 5520212. DOI: 10.1038/bjc.2017.150. View

17.

Al-Saraireh Y, Alshammari F, Youssef A, Al-Tarawneh F, Al-Sarayreh S, Almuhaisen G . Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers. Breast Cancer (Dove Med Press). 2021; 13:565-574. PMC: 8502010. DOI: 10.2147/BCTT.S329770. View

18.

Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li C . MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. Br J Surg. 2017; 105(1):75-85. DOI: 10.1002/bjs.10646. View

19.

Okcu O, Sen B, Ozturk C, Guvendi G, Bedir R . GLUT-1 Expression in Breast Cancer. Turk Patoloji Derg. 2021; 38(2):114-121. PMC: 9999698. DOI: 10.5146/tjpath.2021.01557. View

20.

Oh Y, Seo Y . A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function. Oncol Rep. 2017; 38(4):2343-2350. DOI: 10.3892/or.2017.5925. View